Published in Blood Weekly, May 20th, 2004
The study will evaluate different regimens of combination therapy in patients with hepatitis C who failed to generate a sustained virological response after treatment with Peg-Intron/Rebetol therapy. Patients in the new study will receive Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), already approved as a first-line treatment for patients with hepatitis C.
The REPEAT Trial (retreatment with Pegasys in patients not responding to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.